These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2399526)
1. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619. Johnson GJ; Leis LA; Francis GS Thromb Res; 1990 Jul; 59(1):139-48. PubMed ID: 2399526 [TBL] [Abstract][Full Text] [Related]
2. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets. Johnson GJ; Leis LA; Francis GS Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784 [TBL] [Abstract][Full Text] [Related]
4. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor. Johnson GJ; Dunlop PC; Leis LA; From AH Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295 [TBL] [Abstract][Full Text] [Related]
5. Influence of verapamil and diltiazem on aggregatory responses in cat and rabbit platelet rich plasma. Lippton HL; Horwitz PM; McNamara DB; Landry AZ; Kadowitz PJ Prostaglandins Leukot Med; 1984 Oct; 16(1):121-30. PubMed ID: 6440150 [TBL] [Abstract][Full Text] [Related]
6. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. Rostagno C; Abbate R; Gensini GF; Coppo M; Prisco D; Boddi M; Neri Serneri GG Thromb Res; 1991 Aug; 63(4):457-62. PubMed ID: 1754998 [No Abstract] [Full Text] [Related]
7. Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: an in vivo double blind randomized study. Rostagno C; Prisco D; Paniccia R; Costanzo G; Poggesi L; Boddi M; Abbate R Thromb Res; 1990 Aug; 59(3):531-9. PubMed ID: 2237825 [TBL] [Abstract][Full Text] [Related]
8. Effects of prostaglandins, cAMP, and changes in cytosolic calcium on platelet aggregation induced by a thromboxane A2 mimic (U46619). Yun JC; Ohman KP; Gill JR; Keiser H Can J Physiol Pharmacol; 1991 May; 69(5):599-604. PubMed ID: 1650650 [TBL] [Abstract][Full Text] [Related]
9. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle. Shaw LA; Batey AJ; Coker SJ Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543 [TBL] [Abstract][Full Text] [Related]
10. Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists. Bush LR; Smith SG Thromb Res; 1986 Nov; 44(3):377-89. PubMed ID: 2948294 [TBL] [Abstract][Full Text] [Related]
11. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. Glusa E; Bevan J; Heptinstall S Thromb Res; 1989 Jul; 55(2):239-245. PubMed ID: 2528843 [TBL] [Abstract][Full Text] [Related]
12. Dual effects of nimesulide, a COX-2 inhibitor, in human platelets. Saeed SA; Afzal MN; Shah BH Life Sci; 1998; 63(20):1835-41. PubMed ID: 9820127 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of endothelial cells and calcium channel blockers on platelet aggregation. Yamada Y; Furui H; Furumichi T; Suzuki T; Yamauchi K; Yokota M; Hayashi H; Saito H Jpn Heart J; 1990 Mar; 31(2):201-15. PubMed ID: 2113109 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: studies with aequorin and quin2. Ware JA; Johnson PC; Smith M; Salzman EW Circ Res; 1986 Jul; 59(1):39-42. PubMed ID: 3089642 [TBL] [Abstract][Full Text] [Related]
15. Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation. Timar J; Chopra H; Rong X; Hatfield JS; Fligiel SE; Onoda JM; Taylor JD; Honn KV J Cancer Res Clin Oncol; 1992; 118(6):425-34. PubMed ID: 1377695 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade. Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894 [TBL] [Abstract][Full Text] [Related]
17. Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets. Vinge E; Andersson TL; Larsson B Acta Physiol Scand; 1988 Jul; 133(3):407-16. PubMed ID: 2906509 [TBL] [Abstract][Full Text] [Related]
18. Comparison of verapamil and nifedipine in thrombosis models. Myers AK; Forman G; Torres Duarte AP; Penhos J; Ramwell P Proc Soc Exp Biol Med; 1986 Oct; 183(1):86-91. PubMed ID: 3092231 [TBL] [Abstract][Full Text] [Related]
19. Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats. Erdemli O; Hao Q; Cai B; Lippton HL; Hyman A Arch Int Pharmacodyn Ther; 1994; 328(2):165-79. PubMed ID: 7535994 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers. Moore JB; Fuller BL; Falotico R; Tolman EL Thromb Res; 1985 Nov; 40(3):401-11. PubMed ID: 2417362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]